| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911008 | Lung Cancer | 2014 | 6 Pages |
Abstract
In EGFR-mutant patients, frontline EGFR-TKI significantly reduced the sensitivity of subsequent chemotherapy compared with that of TKI-naïve frontline chemotherapy. These findings need to be validated in further randomized trials.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Zhu Zeng, Hong-hong Yan, Xu-chao Zhang, Wen-zhao Zhong, Yan-yan He, Jin-lin Guan, Fei-yu Niu, Zhi Xie, Yi-sheng Huang, Chong-rui Xu, Song Dong, Yi-long Wu,